The tolerability and safety profile of famotidine

Colin Howden, Guido N.J. Tytgat

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients worldwide have been treated with famotidine. We present a comprehensive safety profile of oral famotidine, incorporating data from investigational trials, postmarketing studies, and reports of marketed use. The excellent tolerability profile of famotidine observed during investigational trials has remained substantially unchanged during postmarketing experience. Famotidine does not notably bind to cytochrome P-450 or gastric alcohol dehydrogenase and therefore has not been associated with clinically significant drug interactions. It is generally well tolerated in patients with cardiovascular, renal, or hepatic dysfunction or with Zollinger-Ellison syndrome who have tolerated doses up to 800 mg daily.

Original languageEnglish (US)
Pages (from-to)36-54
Number of pages19
JournalClinical Therapeutics
Volume18
Issue number1
StatePublished - Jan 1 1996

Fingerprint

Famotidine
Safety
Zollinger-Ellison Syndrome
Alcohol Dehydrogenase
Stomach Ulcer
Duodenal Ulcer
Gastroesophageal Reflux
Drug Interactions
Cytochrome P-450 Enzyme System
Stomach
Kidney
Acids
Liver
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The tolerability and safety profile of famotidine. / Howden, Colin; Tytgat, Guido N.J.

In: Clinical Therapeutics, Vol. 18, No. 1, 01.01.1996, p. 36-54.

Research output: Contribution to journalArticle

Howden, C & Tytgat, GNJ 1996, 'The tolerability and safety profile of famotidine', Clinical Therapeutics, vol. 18, no. 1, pp. 36-54.
Howden, Colin ; Tytgat, Guido N.J. / The tolerability and safety profile of famotidine. In: Clinical Therapeutics. 1996 ; Vol. 18, No. 1. pp. 36-54.
@article{ba6fc03dd9e54ca88b8f6628f59b8772,
title = "The tolerability and safety profile of famotidine",
abstract = "Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients worldwide have been treated with famotidine. We present a comprehensive safety profile of oral famotidine, incorporating data from investigational trials, postmarketing studies, and reports of marketed use. The excellent tolerability profile of famotidine observed during investigational trials has remained substantially unchanged during postmarketing experience. Famotidine does not notably bind to cytochrome P-450 or gastric alcohol dehydrogenase and therefore has not been associated with clinically significant drug interactions. It is generally well tolerated in patients with cardiovascular, renal, or hepatic dysfunction or with Zollinger-Ellison syndrome who have tolerated doses up to 800 mg daily.",
author = "Colin Howden and Tytgat, {Guido N.J.}",
year = "1996",
month = "1",
day = "1",
language = "English (US)",
volume = "18",
pages = "36--54",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - The tolerability and safety profile of famotidine

AU - Howden, Colin

AU - Tytgat, Guido N.J.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients worldwide have been treated with famotidine. We present a comprehensive safety profile of oral famotidine, incorporating data from investigational trials, postmarketing studies, and reports of marketed use. The excellent tolerability profile of famotidine observed during investigational trials has remained substantially unchanged during postmarketing experience. Famotidine does not notably bind to cytochrome P-450 or gastric alcohol dehydrogenase and therefore has not been associated with clinically significant drug interactions. It is generally well tolerated in patients with cardiovascular, renal, or hepatic dysfunction or with Zollinger-Ellison syndrome who have tolerated doses up to 800 mg daily.

AB - Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients worldwide have been treated with famotidine. We present a comprehensive safety profile of oral famotidine, incorporating data from investigational trials, postmarketing studies, and reports of marketed use. The excellent tolerability profile of famotidine observed during investigational trials has remained substantially unchanged during postmarketing experience. Famotidine does not notably bind to cytochrome P-450 or gastric alcohol dehydrogenase and therefore has not been associated with clinically significant drug interactions. It is generally well tolerated in patients with cardiovascular, renal, or hepatic dysfunction or with Zollinger-Ellison syndrome who have tolerated doses up to 800 mg daily.

UR - http://www.scopus.com/inward/record.url?scp=0029848806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029848806&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 36

EP - 54

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -